University of Salford

About: University of Salford is a education organization based out in Salford, Manchester, United Kingdom. It is known for research contribution in the topics: Population & Context (language use). The organization has 13049 authors who have published 22957 publications receiving 537330 citations. The organization is also known as: University of Salford Manchester & The University of Salford Manchester.

Cognitive dysfunction after minor surgery in the elderly

Abstract: Keywords:General anesthesia;minor surgery;out-patient surgery;cognitive dysfunction Background: Major surgery is frequently associated with postoperative cognitive dysfunction (POCD) in elderly patients. Type of surgery and hospitalization may be important prognostic factors. The aims of the study were to find the incidence and risk factors for POCD in elderly patients undergoing minor surgery. Methods: We enrolled 372 patients aged greater than 60 years scheduled for minor surgery under general anesthesia. According to local practice, patients were allocated to either in- (199) or out-patient (173) care. Cognitive function was assessed using neuropsychological testing preoperatively and 7 days and 3 months postoperatively. Postoperative cognitive dysfunction was defined using Z-score analysis. Results: At 7 days, the incidence (confidence interval) of POCD in patients undergoing minor surgery was 6.8% (4.3–10.1). At 3 months the incidence of POCD was 6.6% (4.1–10.0). Logistic regression analysis identified the following significant risk factors: age greater than 70 years (odds ratio [OR]: 3.8 [1.7–8.7], P = 0.01) and in- vs. out-patient surgery (OR: 2.8 [1.2–6.3], P = 0.04). Conclusions: Our finding of less cognitive dysfunction in the first postoperative week in elderly patients undergoing minor surgery on an out-patient basis supports a strategy of avoiding hospitalization of older patients when possible.

Satellite remote sensing of forest resources: three decades of research development

Abstract: Three decades have passed since the launch of the first international satellite sensor programme designed for monitoring Earth’s resources. Over this period, forest resources have come under increasing pressure, thus their management and use should be underpinned by information on their properties at a number of levels. This paper provides a comprehensive review of how satellite remote sensing has been used in forest resource assessment since the launch of the first Earth resources satellite sensor (ERTS) in 1972. The use of remote sensing in forest resource assessment provides three levels of information; namely (1) the spatial extent of forest cover, which can be used to assess the spatial dynamics of forest cover; (2) forest type and (3) biophysical and biochemical properties of forests. The assessment of forest information over time enables the comprehensive monitoring of forest resources. This paper provides a comprehensive review of how satellite remote sensing has been used to date and, building on...

British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.

Abstract: Psoriasis is a common, persistent, relapsing inflammatory skin disease that can be associated with significant morbidity. Quality of life studies in psoriasis reveal a negative impact on patients comparable with that seen in cancer, arthritis and heart disease.1–5 Patients with severe disease constitute approximately 20–30% of all patients with psoriasis, often require systemic treatment, and represent a major economic burden to the Health Service. All standard systemic therapies for severe disease are associated with the potential for major long-term toxicity, many are expensive, and a proportion of patients has treatmentresistant disease.6 Biological therapies or ‘biologics’ describe agents designed to block specific molecular steps important in the pathogenesis of psoriasis and have emerged over the last 3–5 years as potentially valuable alternative therapeutic options. Currently, biological therapies for psoriasis comprise two main groups: (i) agents targeting the cytokine tumour necrosis factor (TNF)-a (e.g. etanercept, infliximab, adalimumab) and (ii) agents targeting T cells or antigen-presenting cells (e.g. efalizumab, alefacept). Two of these, etanercept (Enbrel) and efalizumab (Raptiva) were licensed in 2004 in the U.K. for patients with moderate to severe psoriasis.